Richard Daniell - 09 Dec 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: Exec. VP, European Commercial
Issuer ticker: TEVA
Reported as of: 09 Dec 2025
Net transaction value: -$1,186,584
SEC form: 4
Accepted by SEC: 11 Dec 2025, 16:09:26 UTC
Prior SEC filing: 07 Mar 2025
Next SEC filing: 29 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell

Key filing fact

Richard Daniell filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 11 Dec 2025.

Key facts

This page summarizes Richard Daniell's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 11 Dec 2025, 16:09.

Change

Previous filing in this sequence was filed on 07 Mar 2025.
Current net transaction value: -$1,186,584.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001726096 Primary reporting owner

Daniell Richard

Relationship: Exec. VP, European Commercial
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell
Signature date: 11 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value: $1,869,505
Shares: +100,457
Change %: +208%
Price: $18.61
Shares after: 148,841
Date: 09 Dec 2025
Ownership: Direct
Footnotes: F1

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value: $255,037
Shares: +15,011
Change %: +10%
Price: $16.99
Shares after: 163,852
Date: 09 Dec 2025
Ownership: Direct
Footnotes: F1

TEVA transaction

Ordinary Shares

Sale

Transaction value: $3,311,126
Shares: -115,468
Change %: -70%
Price: $28.68
Shares after: 48,384
Date: 09 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Stock Options (right to buy)

Options Exercise

Transaction value: $0
Shares: -100,457
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 100,457
Exercise price: $18.61
Footnotes: F1, F3

TEVA transaction Derivative

Stock Options (right to buy)

Options Exercise

Transaction value: $0
Shares: -15,011
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 15,011
Exercise price: $16.99
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.635 to $28.765, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F3

Stock options were granted on February 9, 2018, with 33,485 vested on each of February 9, 2020 and February 9, 2021, and 33,487 vested on February 9, 2022.

Footnote F4

Stock options were granted on September 18, 2017, with 7,505 vested on September 18, 2018, and 7,506 vested on September 18, 2019.